Progressive multiple sclerosis (PMS) remains a challenging condition to treat, with current therapies primarily aimed at slowing disease progression rather than reversing neurological damage. Research into mesenchymal stem cell-derived neurotrophic factor (MSC-NTF) therapy, known as NurOwn, is exploring its potential to address both neuroinflammation and neuronal repair in PMS patients.
A Phase II clinical trial evaluated the safety and preliminary efficacy of MSC-NTF therapy in 20 PMS patients, with 18 receiving treatment. While most participants tolerated the therapy, two experienced complications, including one case of arachnoiditis. MRI scans confirmed lumbar nerve root clumping in these cases, though symptoms improved with treatment. No participants experienced MS relapses or significant changes in vital health markers following the therapy.
In terms of efficacy, the study assessed functional improvements using the timed 25-foot walk test (T25FW), nine-hole peg test (9-HPT), and other mobility and cognitive function measures. Patients showed trends toward improvement in mobility and hand function, while biomarker analysis indicated reduced CNS inflammation and increased levels of neuroprotective factors such as VEGF-A and HGF.
The researchers concluded that MSC-NTF therapy appears to be well-tolerated in stable, non-relapsing PMS patients.
